drugset / Trial / NCT01319903
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
RandomizedSingle-groupDouble-blindTreatment
Summary
The novel humanized monoclonal antibody CaCP29 was developed to control the inflammatory response to various stimuli in humans and espacially during sepsis. Purpose of this phase I clinical trial in healthy human males is to investigate various parameters concerning safety and tolerability of CaCP29 and assess pharmacokinetic and pharmacodynamic parameters.
Timeline
- Start
- 2011-03
- Primary completion
- 2011-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | vilobelimab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.